Schizophrenia is a complex psychiatric disorder with a high heritability. The exact mechanism and risk factors for this disease have not been sufficiently resolved despite decades of extensive study. 1 Recently, two genome-wide association studies (GWAS) in Han Chinese identified a total of nine single-nucleotide polymorphisms (SNPs) that reached genome-wide significance level, 2, 3 but none of these risk loci was overlapped in the two studies. We genotyped these SNPs in Han Chinese from Hunan Province, China, and identified no association of any claimed SNP with schizophrenia.
A total of 976 unrelated schizophrenia patients and 1,043 matched healthy controls, all of Han Chinese, were recruited from Hunan Province in Central China. Patients with schizophrenia were diagnosed independently by two psychiatrists according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria. The controls were clinically diagnosed as having no psychiatric disorders or other diseases. All participants or supervisors of patients signed informed consent and this study was approved by the institutional review boards of the Kunming Institute of Zoology and the Second Xiangya Hospital.
The nine SNPs were genotyped by using SNaPshot (Supplementary Table S1 and Supplementary Figure S1 ). No deviation from Hardy--Weinberg equilibrium was observed for each SNP in either cases or controls ( Table 1 ). The SNaPshot results were fully validated in 1% of genotyped individuals who were randomly selected for sequencing. There was no significant difference for allele frequency of the nine SNPs in case--control samples (Table 1) .
Genotype and haplotype associations were conducted by using PLINK. 4 None of the nine SNPs showed a positive association with schizophrenia (P40.05; Table 1 and Supplementary Table S2 ). Note that rs835784 was marginally significant in the dominant model test (P ¼ 0.047; Supplementary Table S2 ), but the significance did not exist after correcting for multiple tests. Haplotype comparison revealed no significant difference between schizophrenia patients and controls (Supplementary Table S3 ). Linkage disequilibrium (LD) analysis showed similar LD pattern in three blocks for the case and control populations, but the overall LD pattern or SNP allele frequency of Chinese populations differed from those of the HapMap data of Africans and Europeans (Supplementary Figure S2 and Supplementary Table S4) , suggesting remarkable ethnic differences.
The lack of validation for any risk SNPs identified in the two GWAS of Han Chinese with schizophrenia 2,3 in our samples was not unexpected, considering the fact that none of the susceptible loci was overlapped in both studies. There are several explanations that would account for the failure to validate the GWAS results.
2,3 First, our sample was not as large as the ones used in both GWAS studies. 2, 3 However, the G* power analysis showed that our sample had sufficient power to detect the potential association between SNPs and schizophrenia (Supplementary Materials and methods). Second, confounding factors such as population stratification might have caused an undetected bias and led to a false result. Moreover, single studies (even if based on large sample size) might have limited power to detect small gene effects in complex diseases such as schizophrenia. 5 We found no apparent population stratification between our case and control populations based on the principal component analysis of the matrilineal genetic component of our sample and reported Han Chinese populations across China (authors' unpublished data). Comparison of minor allele frequencies of the nine SNPs between our sample and the GWAS cohorts 2, 3 further demonstrated regional difference: significant differences were observed for rs1233710 between our controls and the controls in Yue et al.'s study 3 and for rs2142731 between our case or control samples and the controls in Yue et al.'s study 3 (Supplementary  Table S5 ). It can be tentatively said that regional differences accounted for the failure of independent validation. Our results supported the notion of high genetic heterogeneity of schizophrenia. 1 Excessive number of variants with smaller effect, structural variations, somatic mutations, gene--gene interactions and the effect of environmental factors may also have a crucial role in schizophrenia and account for the missing heritability. 6 There are several limitations in the present study. First, we lacked detailed clinical information for each participant among our patients and reported GWAS cohorts, which prevented us from performing further association analysis between specific psychiatric phenotypes and SNP. Aggregating all patients with different subtypes together as a schizophrenia population may camouflage a real association of SNP with subtype. Second, we did not perform a fine-grained analysis for those regions that contained reported susceptible SNPs with a higher density of SNP coverage. Other SNPs, than the reported risk SNPs, in the candidate region/gene may account for the association with schizophrenia in different populations. In spite of these limitations, our current study provided useful data for future meta-analysis of these psychosis markers. Do we have the courage to perform a validation study of risk SNPs distilled from GWAS? Apparently, this will be and will continue to be a challenging question for any validation study.
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